Rapid response of APC/TP53/KRAS mutated stage IV colorectal cancer under FOLFIRI + Bevacizumab detected by liquid biopsy: a case report
|Study ID||Alternative Stable ID||Type|
Study Datasets 2 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
WES using IDT xGen Research Exome on Illumina NovaSeq 2x150bp: Normal sample (buffy coat), cecum tumor biopsy at diagnosis, ileocecal valve region tumor sample at week 19, pericolonic metastasis at week 19, lymph node metastasis at week 19, peritoneal metastasis at week 19. Week 19 samples from hemicolectomy. Deep coverage cfDNA NGS using PanCeq pan-cancer panel on NextSeq 2x150bp: week 2 and week 10.
|Illumina NovaSeq 6000,NextSeq 500||8|
42 NGS libraries of a 13y/o FFPE sample, a tissue-and-patient-matched FF sample, and a GIAB sample (NA12878). In technical replicates (untreated DNA, treated DNA, two different library types, at least library duplicates for each case). Illumina NextSeq, HiSeq and NovaSeq paired-end sequencing.
|Illumina HiSeq 4000,Illumina NovaSeq 6000,NextSeq 500||157|